|
Neonatal Intensive Care Drug Manual
|
| bet | 455/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Practice points
|
|
References
|
Slaughter LA, Patel AD, Slaughter JL. Pharmacological treatment of neonatal seizures: a systematic review. Journal of child neurology. 2013;28:351-64.
Painter MJ, Scher MS, Stein AD, Armatti S, Wang Z, Gardiner JC, Paneth N, Minnigh B, Alvin J. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. The New England journal of medicine. 1999;341:485-9.
Pathak G, Upadhyay A, Pathak U, Chawla D, Goel SP. Phenobarbitone versus phenytoin for treatment of neonatal seizures: an open-label randomized controlled trial. Indian pediatrics. 2013;50:753-7.
Osborn DA, Jeffery HE, Cole MJ. Sedatives for opiate withdrawal in newborn infants. Cochrane database of systematic reviews. 2010:CD002053.
National clinical guidelines for the management of drug use during pregnancy, birth and the early development years of the newborn. Ministerial Council on Drug Strategy; 2006.
Guidelines for the management of substance use during pregnancy birth and the postnatal period. NSW Ministry of Health; 2014.
Malik D, Khan SH, Ali SW, Rather TA, Pakala R, Hassan MU, Yadav N, Pasupula M. Comparison of phenobarbitone and ursodeoxycholic acid in drug-augmented hepatobiliary scintigraphy for excluding the diagnosis of obstructive cholestasis in neonatal cholestasis syndrome. Nuclear medicine communications. 2015;36:827-32.
Cies JJ, Giamalis JN. Treatment of cholestatic pruritus in children. Am J Health-Syst Pharm. 2007;64:1157-62.
Gilman JT, Gal P, Duchowny MS, Weaver RL, Ransom JL. Rapid sequential phenobarbital treatment of neonatal seizures. Pediatrics. 1989;83:674-8.
Yukawa M, Yukawa E, Suematsu F, Takiguchi T, Ikeda H, Aki H, Mimemoto M. Population pharmacokinetics of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants: an update. J Clin Pharm Ther. 2011;36:704-10.
Marsot A, Brevaut-Malaty V, Vialet R, Boulamery A, Bruguerolle B, Simon N. Pharmacokinetics and absolute bioavailability of phenobarbital in neonates and young infants, a population pharmacokinetic modelling approach. Fundam Clin Pharmacol. 2014;28:465-71.
Filippi L, la Marca G, Cavallaro G, Fiorini P, Favelli F, Malvagia S, Donzelli G, Guerrini R. Phenobarbital for neonatal seizures in hypoxic ischemic encephalopathy: a pharmacokinetic study during whole body hypothermia. Epilepsia. 2011;52:794-801.
Shellhaas RA, Ng CM, Dillon CH, Barks JD, Bhatt-Mehta V. Population pharmacokinetics of phenobarbital in infants with neonatal encephalopathy treated with therapeutic hypothermia. Pediatr Crit Care Med. 2013;14:194-202.
van den Broek MP, Groenendaal F, Toet MC, van Straaten HL, van Hasselt JG, Huitema AD, de Vries LS, Egberts AC, Rademaker CM. Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach. Clin Pharmacokinet. 2012;51:671-9.
Alonso Gonzalez AC, Ortega Valin L, Santos Buelga D, Garcia Sanchez MJ, Santos Borbujo J, Monzon Corral L, Dominguez-Gil Hurle A. Dosage programming of phenobarbital in neonatal seizures. J Clin Pharm Ther 1993;18(4):267-70.
Micromedex® 2.0, (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com.acs.hcn.com.au/ (cited: 06/2016).
Australian Injectable Drugs Handbook, 6th Edition, Society of Hospital Pharmacists of Australia 2014.
St. Louis EK, Gidal BE, Henry TR, Kaydanova Y,Krumholz A, McCabe PH, et al. Conversions between monotherapies in epilepsy: Expert consensus. Epilepsy and Behaviour 2007;11:222-234
|
Original version Date: 21/06/2016
|
Author: Neonatal Medicines Formulary Consensus Group
|
Current Version number: 2
|
Version Date: 16/11/2020
|
Risk Rating: Low
|
Due for Review: 16/11/2025
|
Approved by: DTC
|
Approval Date: TBA
|
|
| |
